11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Naltrexon Hydrochloride Accord

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Naltrexon

Naltrexon

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-60.

  2. Folkhälsan i Sverige Årsrapport 2014. Folkhalsomyndigheten [www]. [updated 2015-12-28, cited 2016-04-19].

  3. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - VIVTROL (naltrexone). Food and Drug Administration [www]. [updated 2006-04-13, cited 2016-04-01].

  4. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617-25.

  5. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-17.

  6. Greenfield SF, Pettinati HM, O'Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34:1803-12.

  7. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101:1451-62.

  8. Morley KC, Teesson M, Sannibale C, Baillie A, Haber PS. Clinical predictors of outcome from an Australian pharmacological relapse prevention trial. Alcohol Alcohol. 2010;45:520-6.

  9. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92-9.

  10. Kiefer F, Jahn H, Wiedemann K. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment. Pharmacopsychiatry. 2005;38:184-6.

  11. Setiawan E, Pihl RO, Cox SM, Gianoulakis C, Palmour RM, Benkelfat C et al. The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. Alcohol Clin Exp Res. 2011;35:1134-41.

  12. NALTREXONE (naltrexonhydroklorid). Summary of Product Characteristics. Medical Products Agency (MPA); 2014.

  13. Food and Drug Administration (FDA). Labeling - NALTREXONE HYDROCHLORIDE (naltrexone hydrochloride). Food and Drug Administration [www]. [updated 2016-04-12, cited 2016-04-01].

  14. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506-13.

  15. Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2012;1:CD006219.

  16. King AC, Cao D, O'Malley SS, Kranzler HR, Cai X, deWit H et al. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol. 2012;32:630-6.

  17. King AC, Cao D, Zhang L, O'Malley SS. Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. Biol Psychiatry. 2013;73:924-30.

  18. Fonsi Elbreder M, de Souza e Silva R, Pillon SC, Laranjeira R. Alcohol dependence: analysis of factors associated with retention of patients in outpatient treatment. Alcohol Alcohol. 2011;46:74-6.

  19. Harris AH, Kivlahan DR, Bowe T, Humphreys KN. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv. 2010;61:392-8.

  20. Socialstyrelsens statistikdatabas . Stockholm: Socialstyrelsen. 2014 [cited 2016-02-17.]

  1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-60.
  2. Folkhälsan i Sverige Årsrapport 2014. Folkhalsomyndigheten [www]. [updated 2015-12-28, cited 2016-04-19].
  3. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - VIVTROL (naltrexone). Food and Drug Administration [www]. [updated 2006-04-13, cited 2016-04-01].
  4. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617-25.
  5. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-17.
  6. Greenfield SF, Pettinati HM, O'Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34:1803-12.
  7. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101:1451-62.
  8. Morley KC, Teesson M, Sannibale C, Baillie A, Haber PS. Clinical predictors of outcome from an Australian pharmacological relapse prevention trial. Alcohol Alcohol. 2010;45:520-6.
  9. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92-9.
  10. Kiefer F, Jahn H, Wiedemann K. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment. Pharmacopsychiatry. 2005;38:184-6.
  11. Setiawan E, Pihl RO, Cox SM, Gianoulakis C, Palmour RM, Benkelfat C et al. The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. Alcohol Clin Exp Res. 2011;35:1134-41.
  12. NALTREXONE (naltrexonhydroklorid). Summary of Product Characteristics. Medical Products Agency (MPA); 2014.
  13. Food and Drug Administration (FDA). Labeling - NALTREXONE HYDROCHLORIDE (naltrexone hydrochloride). Food and Drug Administration [www]. [updated 2016-04-12, cited 2016-04-01].
  14. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506-13.
  15. Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2012;1:CD006219.
  16. King AC, Cao D, O'Malley SS, Kranzler HR, Cai X, deWit H et al. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol. 2012;32:630-6.
  17. King AC, Cao D, Zhang L, O'Malley SS. Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. Biol Psychiatry. 2013;73:924-30.
  18. Fonsi Elbreder M, de Souza e Silva R, Pillon SC, Laranjeira R. Alcohol dependence: analysis of factors associated with retention of patients in outpatient treatment. Alcohol Alcohol. 2011;46:74-6.
  19. Harris AH, Kivlahan DR, Bowe T, Humphreys KN. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv. 2010;61:392-8.
  20. Socialstyrelsens statistikdatabas . Stockholm: Socialstyrelsen. 2014 [cited 2016-02-17.]